{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Defined as participants having as best response complete hematologic response (CHR) or CHR with incomplete platelet recovery (CHRp). Criteria: CHR-WBC in Peripheral Blood (PB):≤ULN; Immature cells in PB:No blasts, promyelocytes, myelocytes, metamyelocytes; Platelet count (untransfused):≥100,000/mm\\^3 and ≤450,000/mm\\^3; ANC:≥ 1000/mm\\^3; Blasts in BM:\\<5%; Extra medullary disease:No extramedullary leukemia, including no hepato or splenomegaly (regardless of CNS involvement). CHRp-CHR except platelet count (untransfused) \\& ANC:20,000/mm\\^3 ≤platelet \\<100,000/mm\\^3 \\& /or 500/mm\\^3 ≤ANC ≤1000/mm\\^3.","groups":[{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG000","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 60 mg/m^2)"},{"description":"Participants with imatinib-resistant or imatinib-intolerant Ph+ CML in accelerated phase (AP), or in myeloid blast phase (MBP), or in lymphoid blast phase (LBP); or relapsed or refractory Ph+ acute lymphoblastic leukemia (ALL) after imatinib use; or second or subsequent relapse of Ph+ acute myeloid leukemia (AML). Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG001","title":"Stratum 2/3 Ph+ ALL or AP/BP-CML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 60 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG002","title":"Stratum 4 Ph- ALL/AML (Dasatinib 60 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 80 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG003","title":"Stratum 4 Ph- ALL/AML (Dasatinib 80 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 100 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG004","title":"Stratum 4 Ph- ALL/AML (Dasatinib 100 mg/m^2)"},{"description":"Participants with second or subsequent relapse of Ph- ALL or Ph- AML. Dasatinib 120 mg/m\\^2 QD, as long as clinical benefit was maintained.","id":"OG005","title":"Stratum 4 Ph- ALL/AML (Dasatinib 120 mg/m^2)"}],"paramType":"NUMBER","populationDescription":"All treated participants in strata 2/3 and 4: Participants who received at least 1 dose of study therapy.","reportingStatus":"POSTED","timeFrame":"Days 8, 15, 22, 29, 36, 43; Weeks 4, 7, 13, 19, 25, 31, 37; at Week 10 (only stratum 4); then every 12 weeks upto 24 months; then once/year; EOT(Median duration of therapy in months: Stratum 2/3=3.02 [Range: 0.53-37.72]; Stratum 4=1.14 [Range: 0.03-3.38])","title":"Number of Participants With Major Hematologic Response (MaHR) at Any Time in Stratum 2/3 (Ph+ ALL or AP/BP-CML) and Stratum 4 (Ph- ALL/AML)","type":"SECONDARY","unitOfMeasure":"participants"}